Valentin Feichtenschlager, MD
|
|
| Title(s) | Associate Specialist, Dermatology |
|---|
| School | School of Medicine |
|---|
| Address | 2340 Sutter Street, #N469
San Francisco CA 94115
|
|---|
| Phone | 415-425-0890 |
|---|
| vCard | Download vCard |
|---|
|
|
Bibliographic
Altmetrics Details
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
LB1005 Suppression of NRAS-mutant melanoma growth with NRAS-targeting ASO treatment reveals therapeutically relevant kinase co-dependencies. Journal of Investigative Dermatology. 2024 Aug 1; 144(8):s177.
FEICHTENSCHLAGER FV, Zheng ZY, Qu QT, Hohlova HD, Callanan CC, Chen CL, Chen CC, Ho HW, Lee LA, Hwang HY, Muñoz MD, Rappersberger RK, Coppe CJ, Ortiz-Urda OS. .
View in:
Publisher Site Mentions:
-
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma. Mol Cancer. 2024 02 22; 23(1):40.
Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, Daud A, Rappersberger K, Kohwi-Shigematsu T, Coppé JP, Ortiz-Urda S. PMID: 38383439; PMCID: PMC10882889.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansAnimalsCells
-
The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma. Res Sq. 2023 Dec 01.
Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, Daud A, Rappersberger K, Kohwi-Shigematsu T, Coppé JP, Ortiz-Urda S. PMID: 38077055; PMCID: PMC10705697.
View in:
PubMed Mentions:
-
Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment. Oncotarget. 2023 05 26; 14:543-560.
Feichtenschlager V, Zheng YJ, Ho W, Chen L, Callanan C, Chen C, Lee A, Ortiz J, Rappersberger K, Ortiz-Urda S. PMID: 37235843; PMCID: PMC10219656.
View in:
PubMed Mentions:
5 Fields:
Translation:
HumansAnimalsCells
-
672 Targeting lncRNAs AC and BX reveals their critical role in melanoma and allows to identify novel phosphor-catalytic vulnerabilities. Journal of Investigative Dermatology. 2020 Jul 1; 140(7):s91.
Feichtenschlager FV, Emily EC, Vujic VM, Vujic VI, Chen CC, Lee LA, Ortiz-Urda OS. .
View in:
Publisher Site Mentions:
-
Clinical melanoma characteristics and survival-a single-center retrospective study between 2000 and 2010. Wien Med Wochenschr. 2019 Oct; 169(13-14):323-330.
Feichtenschlager V, Weihsengruber F, Richter L, Vujic I, Rappersberger K, Posch C. PMID: 30649651.
View in:
PubMed Mentions:
1 Fields:
Translation:
Humans
-
185 The antisense lncRNA transcript RP11-7O11.3: Shedding light upon a novel and crucial player in NRAS mutant melanoma. Journal of Investigative Dermatology. 2018 May 1; 138(5):s31.
Chen CL, Feichtenschlager FV, Vujic VM, Lee LA, Kao KH, Zheng ZJ, Ortiz OS. .
View in:
Publisher Site Mentions:
-
184 Discovering the hidden elements of cancer: Targeting the lncrna ac004540.4 reveals its critical role in nras mutant melanoma. Journal of Investigative Dermatology. 2018 May 1; 138(5):s31.
Feichtenschlager FV, Chen CL, Vujic VM, Lee LA, Kao KH, Zheng ZJ, Ortiz OS. .
View in:
Publisher Site Mentions:
-
497 Eleven years of melanoma patient management – observations and trends from a single-center study in Austria. Journal of Investigative Dermatology. 2016 Sep 1; 136(9):s245.
Posch PC, Feichtenschlager FV, Weihsengruber WF, Rappersberger RK. .
View in:
Publisher Site Mentions:
-
Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. Oncotarget. 2014 Sep 15; 5(17):7936-44.
Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM. PMID: 25277205; PMCID: PMC4202171.
View in:
PubMed Mentions:
19 Fields:
Translation:
HumansCells
-
Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer. 2014 Mar 18; 110(6):1427-32.
Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. PMID: 24518593; PMCID: PMC3960625.
View in:
PubMed Mentions:
12 Fields:
Translation:
Humans
-
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 05; 110(10):4015-20.
Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. PMID: 23431193; PMCID: PMC3593920.
View in:
PubMed Mentions:
126 Fields:
Translation:
HumansAnimalsCells
This graph shows the total number of publications by year. To see the data as text,
click here.
This graph shows the total number of publications by year. To return to the graph,
click here.
| Year | Publications |
|---|
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 2 |
| 2024 | 2 |
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text,
click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text,
click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs